Brief: Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
09/04/2025 12:03
April 9 (Reuters) - Atea Pharmaceuticals Inc AVIR.O: ATEA PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN C-BEYOND, PHASE 3 STUDY EVALUATING REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS Source text: ID:nGNX8b2PGy Further company coverage: AVIR.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM